Related Experiment Video

Updated: Aug 24, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to

Jie Lu1, Setsuko Kunimoto, Yohko Yamazaki

  • 1Investigative Treatment Division, National Cancer Center Research Institute East, Chiba 277-8577, Japan.

Cancer Science
|June 9, 2004
PubMed

Insights

Researchers identified kigamicin D, a compound that selectively kills cancer cells during nutrient starvation. This discovery supports a new anti-austerity cancer therapy strategy targeting tumor cells

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Cancer progression relies on angiogenesis and nutrient starvation tolerance due to inadequate nutrient supply.
  • Cancer cells' unique ability to survive nutrient deprivation presents a potential therapeutic target.
  • Targeting cancer cell austerity offers a novel strategy for cancer treatment.

Purpose of the Study:

  • To develop and implement an anti-austerity strategy to eliminate cancer cells' tolerance to nutrient starvation.
  • To screen for compounds that selectively inhibit cancer cell viability under nutrient-deprived conditions.

Main Methods:

  • Developed a screening method using PANC-1 cells in nutrient-rich and nutrient-deprived media.
  • Screened over 2000 actinomycete culture media for potential anti-cancer agents.
  • Evaluated the efficacy of identified compounds in preclinical cancer models.

Main Results:

  • Identified kigamicin D, a compound exhibiting preferential cytotoxicity to cancer cells under nutrient deprivation.
  • Kigamicin D demonstrated significant suppression of pancreatic cancer tumor growth in vivo.
  • Kigamicin D was found to inhibit Akt activation induced by nutrient starvation.

Conclusions:

  • Kigamicin D is a promising candidate for the novel anti-austerity cancer therapy strategy.
  • This approach targets cancer cells' specific adaptation to nutrient starvation.
  • Further research into kigamicin D and anti-austerity strategies may lead to new cancer treatments.

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...